✦ LIBER ✦

Association between tumor necrosis factor receptor II and familial, but not sporadic, rheumatoid arthritis: Evidence for genetic heterogeneity

✍ Scribed by Philippe Dieudé; Elisabeth Petit; Séverine Cailleau-Moindrault; José Osorio; Céline Pierlot; Maria Martinez; Sabine Fauré; Olivier Alibert; Sandra Lasbleiz; Claudia De Toma; Thomas Bardin; Bernard Prum; François Cornélis; European Consortium on Rheumatoid Arthritis Families

Publisher: John Wiley and Sons
Year: 2002
Tongue: English
Weight: 71 KB
Volume: 46
Category: Article
ISSN: 0004-3591
DOI: 10.1002/art.10101

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Association between rheumatoid arthritis

Association between rheumatoid arthritis and polymorphism of tumor necrosis factor receptor II, but not tumor necrosis factor receptor I, in Caucasians

✍ Anne Barton; Sally John; W. E. R. Ollier; Alan Silman; Jane Worthington 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB 👁 2 views

Tumor necrosis factor receptor type II (

Tumor necrosis factor receptor type II (exon 6) and interleukin-6 (−174) gene polymorphisms are not associated with family history but tumor necrosis factor receptor type II is associated with hypertension in patients with rheumatoid arthritis from northern Sweden

✍ Solbritt Rantapää Dahlqvist; Lisbeth Ärlestig; Carin Sikström; Solveig Linghult 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB 👁 1 views

No evidence of association between anti–

No evidence of association between anti–tumor necrosis factor treatment and mortality in patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register

✍ Mark Lunt; Kath D. Watson; William G. Dixon; British Society for Rheumatology Bi 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 100 KB 👁 1 views

## Objective To study the association between anti–tumor necrosis factor (anti-TNF) therapy and mortality in a national cohort of patients with rheumatoid arthritis. ## Methods We prospectively followed up 12,672 patients who were beginning anti-TNF therapy and 3,522 biologic-naive patients recei